30 patients with Wiskott-Aldrich syndrome have been treated with etuvetidigene autotemcel. Credit: Telethon Foundation via LinkedIn. Italian research charity Telethon Foundation is one step closer to ...

All of a sudden, Amgen stock is up 15% since late December to around $299. Its rise helped push up the healthcare sector up just over 7% since hitting a bottom in late December. The better-than ...

On Wednesday, Erste Group upgraded shares of biotechnology firm Amgen (NASDAQ:AMGN) from Hold to Buy. The upgrade was primarily attributed to Amgen's financial performance, which includes a higher ...

TORONTO - Canada’s main stock index gained almost 300 points Wednesday on widespread market strength, while U.S. stocks rose after a mixed trading day. The S&P/TSX composite index closed up ...

On Wednesday, Erste Group upgraded shares of biotechnology firm Amgen (NASDAQ:AMGN) from Hold to Buy. The upgrade was primarily attributed to Amgen's financial performance, which includes a higher ...

RBC Capital analyst Gregory Renza maintained a Buy rating on Amgen (AMGN – Research Report) yesterday and set a price target of $320.00. The company’s shares closed yesterday at $289.02.

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term competition thanks to a new agreement between Amgen and Celltrion. Late last week ...

Celltrion Inc.’s biosimilar versions of Amgen Inc.’s blockbuster bone-strengthening drugs Prolia and Xgeva are blocked in the US until June 1 as part of a settlement agreement, according to a filing ...